UK markets open in 2 hours 14 minutes
  • NIKKEI 225

    23,407.12
    -78.68 (-0.34%)
     
  • HANG SENG

    24,757.85
    -29.34 (-0.12%)
     
  • CRUDE OIL

    38.74
    -0.83 (-2.10%)
     
  • GOLD FUTURES

    1,910.00
    -1.90 (-0.10%)
     
  • DOW

    27,463.19
    -222.19 (-0.80%)
     
  • BTC-GBP

    10,508.91
    -12.04 (-0.11%)
     
  • CMC Crypto 200

    271.11
    +9.82 (+3.76%)
     
  • ^IXIC

    11,431.35
    +72.41 (+0.64%)
     
  • ^FTAS

    3,233.99
    -37.09 (-1.13%)
     

The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4%

ReportLinker
·6-min read

Increasing implication of mouse clinical trials (MCTs) and ongoing innovation in mice models are set to drive the mice model market. ’’. The global mice model market size is projected to reach USD 1.

New York, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Mice Model Market by Mice Type, Technology, Application, Service, Care Products, Region - Global Forecast to 2025" - https://www.reportlinker.com/p04756165/?utm_source=GNW
9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period. The major factors driving the growth of this market are the Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing implications of mouse clinical trials (MCTs) for more predictive outcomes and ongoing innovations in mice models are driving the growth of the global mice model industry. However, Implementation of laws and regulations for animal protection and welfare has enforced restrictive practices and bans on the use of animals for different purposes that may restrict the growth of this market to a certain extent.
By mice type, the genetically engineered mice accounted for the fastest-growing segment of the mice model market.
Genetically engineered mice segment is anticipated to be the fastest-growing due to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models
• By service, the breeding segment accounted for the largest share of the mice model market.

The breeding segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing demand for mice models for drug discovery and development and the subsequent increase in the demand for personalized medicines.

Oncology segment expected to grow at the fastest growth rate during the forecast period.
Based on application, the mice model market has been segmented into oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies.The endocrine disease studies segment is further segmented into diabetes and other endocrine metabolic disease.

The oncology segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.
• By technology type, CRISPR/Cas9 accounted for the largest share of the mice model market

CRISPR is the most widely used technology in the mice model market and contributed to the largest share of the mice model market in 2020. Ease of design, high efficiency, and relatively lower cost have increased the demand for CRISPR-customized mice models.
• By mice care product, cages segment accounted for the largest share of the mice model market

Based on mice care products, the mice model market has been segmented into cages, feed, bedding, and other products (gnotobiotic equipment, water systems, and accessories).The cages segment accounted for the largest share of the mice model market.

This can be attributed to the availability of a wide range of cages designed for specific research needs and the higher cost of cages compared to other care products.

Asia Pacific: The fastest-growing region in the mice model market.

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region.

A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

North America: The largest share of the drug discovery services market.

North America, which includes the US and Canada, accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers - 55%
• By Region— North America - 50%, Europe - 20%, APAC – 20%, RoW- 10%

The mice model market is dominated by a few globally established players such as Charles River Laboratories (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure Bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI GROUP (China), Ozgene Pty Ltd. (Australia), and Harbour Biomed (US).

Research Coverage:
The report segments the mice model market based on region (North America, Asia Pacific, Europe, and RoW), mice type (inbred mice, outbred mice, conditioned/surgically modified mice, hybrid/congenic mice, genetically engineered mice, and spontaneous mutant mice), service (breeding, quarantine, cryopreservation, rederivation, genetic testing, model in-licensing, and other services ((surgical, line rescue, and in vivo pharmacology services)), application (oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies), technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies (virus/vector-mediated gene transfer, and TALENs & ZFNs)) and mice care product (cages, feed, bedding and other products (gnotobiotic equipment, water systems, and accessories)), Company type (Tier 1, tier 2, Tier3 mice providers). The report also provides a comprehensive review of market drivers, challenges, and opportunities in the mice model market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.

The report also helps stakeholders understand the pulse of the mice model market and provides them information on key market drivers, challenges, and opportunities.

Read the full report: https://www.reportlinker.com/p04756165/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001